Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or ObesityDomenica Rubino(Washington Center for Weight Management and Research), Mark Warren(Physicians East)JAMAMarch 23, 202110.1001/jama.2021.3224Cited by 1,195SaveCiteExport RISWatch citationsRelated PapersOral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial|The Lancet|2023|377